Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases
Table 1
Autoimmune disease and therapeutic plasma exchange (TPE) indications.
SLE
N=40 (60.61)
DAH
11 (27.5)
Neuropsychiatric SLE
9 (22.5)
Thrombotic microangiopathy
5 (12.5)
CAPS
4 (10)
Lupus nephritis (WHO Class IV)
4 (10)
Severe skin lupus
2 (5)
Gastrointestinal lupus
1 (2.5)
Severe SLE
1 (2.5)
Type B insulin resistance
1 (2.5)
Evans syndrome
1 (2.5)
Rejection of the kidney allograft
1 (2.5)
ANCA-associated vasculitis type Microscopic polyangiitis
8 (12.12)
DAH
4 (50)
Rapidly progressive glomerulonephritis
4 (50)
DAH plus rapidly progressive glomerulonephritis
2 (25)
ANCA-associated vasculitis type granulomatosis with polyangiitis
4 (6.06)
DAH
2 (50)
Rapidly progressive glomerulonephritis
2 (50)
DAH plus rapidly progressive glomerulonephritis
1 (25)
Inflammatory myopathies
3 (4.54)
Diffuse scleroderma
2 (3.04)
DAH
1 (50)
Severe scleroderma
1 (50)
Autoimmune meningoencephalitis
2 (3.03)
Rheumatoid arthritis
1 (1.52)
Cryoglobulinemia
1 (1.52)
Primary APS
1 (1.52)
CAPS
1 (100)
Goodpasture Syndrome
1 (1.52)
DAH
1 (100)
Devic syndrome
1 (1.52)
Vasculitis
1 (1.52)
CNS Primary Vasculitis
1 (1.52)
Average of therapeutic plasma exchanges
5.39 (3-14)
Median and interquartile range (IQR). SLE: systemic lupus erythematosus; DAH:diffuse alveolar hemorrhage; CAPS: catastrophic antiphospholipid syndrome; WHO: World Health Organization; APS: antiphospholipid syndrome; CNS: central nervous system.
